Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,498
Total Claims
$3.4M
Drug Cost
901
Beneficiaries
$3,775
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-86%
Opioid rate vs peers
0.3% vs 2.2% avg
+167%
Cost per patient vs peers
$3,775 vs $1,411 avg
+35%
Brand preference vs peers
14.4% vs 10.6% avg
Opioid Prescribing
0.3%
Opioid Rate
58
Opioid Claims
$611
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,619 claims · $2.7M
Generic: 15,605 claims · $669K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 403 | $359K |
| Dapagliflozin Propanediol | 214 | $285K |
| Nintedanib Esylate | 18 | $237K |
| Sitagliptin Phosphate | 127 | $195K |
| Empagliflozin | 121 | $194K |
| Dulaglutide | 96 | $151K |
| Metformin Hcl | 37 | $119K |
| Apixaban | 83 | $104K |
| Diclofenac Potassium | 47 | $97K |
| Linaclotide | 94 | $86K |
| Fluticasone/Umeclidin/Vilanter | 80 | $84K |
| Rivaroxaban | 75 | $80K |
| Denosumab | 45 | $77K |
| Insulin Degludec | 60 | $66K |
| Sitagliptin Phos/Metformin Hcl | 49 | $65K |
Prescribing Profile
Patient Profile
75
Avg Age
66%
Female
1.13
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data